Loading
A South Korean study of a sensitive DNA sequencing blood test meant both to find several cancers and to watch for leftover disease after treatment.
Yonsei high-sensitivity circulating tumour DNA test for multi-cancer diagnosis and residual disease (NCT07035587) is an observational study sponsored by Yonsei University. It validates a high-sensitivity sequencing method for early diagnosis and post-treatment monitoring of multiple cancers.
The registry record, read on 29 October 2026, gives its status as recruiting, with an estimated 1,200 participants, a start on 21 August 2024 and primary completion expected on 28 July 2029.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/